Study Stopped
The study was terminated as patients could not be followed-up during the COVID pandemic. Since this was a non-intervention study, as per Johns Hopkins University policy, we had to hold off the patient visits during the pandemic.
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
CAPTURE
1 other identifier
observational
47
1 country
1
Brief Summary
This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedFirst Submitted
Initial submission to the registry
June 10, 2013
CompletedFirst Posted
Study publicly available on registry
June 12, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 11, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 3, 2021
CompletedOctober 12, 2021
May 1, 2021
5.8 years
June 10, 2013
October 8, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean change from baseline in BCVA at 5 and 10 years.
Mean change from baseline in BCVA at 5 and 10 years.
10 years
Secondary Outcomes (1)
Mean change from baseline in foveal thickness at 5 and 10 years
10 years
Study Arms (1)
Treated with Ranibizumab in previous trial
Treated with Ranibizumab in previous trial
Eligibility Criteria
All patients who have been enrolled in the following three trials will be included in the study: A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"
You may qualify if:
- All patients who have been enrolled in the following three trials will be included in the study:
- A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Wilmer Eye Institute
Baltimore, Maryland, 21287, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Campochiaro, MD
Johns Hopkins University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2013
First Posted
June 12, 2013
Study Start
January 1, 2013
Primary Completion
October 11, 2018
Study Completion
March 3, 2021
Last Updated
October 12, 2021
Record last verified: 2021-05